Document is current
Any future updates will be listed below
-
Authors
De Lorenzo, Alberto
Moretti, Giulia Sofia
Bertini, Alessandro
De Lorenzo, Alice
Pisciotta, Chiara
Collet-Vidiella, Roger
Eftimov, Filip
Falzone, Yuri Matteo
Fasolino, Alessandra
Fortanier, Etienne
Gendre, Thierry
Gentile, Francesco
Hadden, Robert D.
Islam, Badrul
Kleopa, Kleopas
Cejas, Luciana Leon
Leonardi, Luca
Mandia, Daniele
Masingue, Marion
Mira, Valentin
Peric, Stojan
Querol, Luis
Rajabally, Yusuf A.
Sevilla, Teresa
Tomaselli, Pedro José
Tozza, Stefano
Bosca, Maria
Brouwer, Matthijs
Cocco, Antoniangela
Cousyn, Louis
De Santis, Tiziana
Gonzalez, Fabio
Lukic, Milica Jecmenica
Mistry, Niraj
Maranzano, Alessio
Morena, Emanuele
Nakano, Frederico Nakane
Olmedo-Saura, Gonzalo
Sechi, Elia
Ticozzi, Nicola
Troisi, Serena
Tsokkos, Tasos
Wittwer, Aymeric
Bianchi, Elisa
Nobile-Orazio, Eduardo
Pareyson, Davide
Doneddu, Pietro Emiliano
- License Information
-
More Information
Article History
Received: 23 June 2025
Accepted: 20 May 2026
First Online: 5 June 2026
Competing interests
: The authors declare no competing non-financial interests but the following competing financial interests. A.B., C.P., and D.P. are members of the EURO-NMD European Reference Network and of the Inherited Neuropathy Consortium RDCRN. E.N.-O. reports personal fees for Advisory or Scientific Board from ArgenX – Belgium, Takeda – Italy and USA, CSL-Behring - Italy and USA, Janssen – USA, Kedrion – Italy, LFB – France, Roche– Switzerland, Sanofi - USA. D.P. has served on advisory boards for Alnylam, Akcea, Arvinas, Augustine Tx, DTx, Inflectis, Novartis, and as local Principal Investigator in clinical trials sponsored by Alnylam, Ionis Pharmaceuticals, Nido Biosciences, and AT Therapeutics; he received speaker honorarium from AstraZeneca. P.E.D. reports personal fees for Advisory from ArgenX, Takeda, and Sanofi, and received travel grants to attend scientific meetings from CSL Behring and Kedrion. R.H. reports personal fees from ArgenX, Takeda, and Dianthus Therapeutics, and payment of costs to attend scientific meetings from Takeda and CSL Behring. T.G. received consulting fees from Alnylam and Janssen; honoraria from Alnylam, Argenx, and CSL Behring; and received travel grants to attend scientific meetings from Alexion, Alnylam, Argenx, CSL Behring, LFB, and Pfizer. L.Q. received research grants from Instituto de Salud Carlos III – Ministry of Economy and Innovation (Spain), CIBERER, Fundació La Marató, GBS-CIDP Foundation International, and ArgenX. L.Q. received speaker or expert testimony honoraria from CSL Behring, Novartis, Sanofi-Genzyme, Merck, Annexon, Alnylam, ArgenX, Dianthus, Biocryst, Montis, LFB, Avilar Therapeutics, Lycia Therapeutics, Nuvig Therapeutics, and Takeda. L.Q. serves on Clinical Trial Steering Committees for Sanofi Genzyme, ArgenX, and Takeda and is Principal Investigator for UCB’s CIDP01 trial and Sanofi’s Mobilize and Vitalize trials. The other authors declare no conflict of interest.
